MedTrace Logo

Clinical Benefits and Safety of Combined Polynucleotides and Hyaluronic Acid - Newest - for Acne Scars Treatment

NCT05936437 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-12

No results posted yet for this study

Summary

This clinical study wants to evaluate the efficacy and safety of a medical device combining "Polynucleotide Highly Purified Technology" (PN-HPT™) and hyaluronic acid (Newest-Mastelli S.r.l) for treating moderate-to-severe atrophic post-acne scars.

Conditions

  • Atrophic Scar

Interventions

DEVICE

Subjects treated with Newest medical device

Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml). Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks.

Sponsors & Collaborators

  • Mastelli S.r.l

    lead INDUSTRY

Principal Investigators

  • Emanuele Bartoletti, MD · Director of the International School of Aesthetic Medicine of the Fatebenefratelli Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-16
Primary Completion
2025-07-24
Completion
2025-07-24

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936437 on ClinicalTrials.gov